Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114367 | 0.77 | NPC1 (0.36) | MAP3K14CRBNDDB1LMNAMAPT | |
| SCHEMBL5855515 | 0.76 | MAP3K14 (0.39) | MAP3K14CRBNDDB1 | |
| SCHEMBL3381432 | 0.76 | MAP3K14 (0.35) | MAP3K14 | |
| SCHEMBL10754755 | 0.73 | MAP3K14 (0.48) | MAP3K14CRBNDDB1CYP19A1LMNA | |
| SCHEMBL8348991 | 0.73 | MAP3K14 (0.48) | MAP3K14CRBNDDB1CYP19A1LMNA | |
| SCHEMBL4985328 | 0.70 | — | — | |
| SCHEMBL2573071 | 0.70 | NPC1 (0.40) | CRBNDDB1LMNAMAPTKMT2A | |
| SCHEMBL5970075 | 0.70 | MAP3K14 (0.34) | MAP3K14 | |
| SCHEMBL6272873 | 0.69 | NPC1 (0.40) | CRBNDDB1LMNAMAPTPKM | |
| SCHEMBL112502 | 0.69 | NPC1 (0.40) | CRBNDDB1LMNAMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4684872-A1 | DEVICE AND METHOD FOR WATER-IN-AIR GENERATION OF DROPLETS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-01-28 | — | — | EP | claimed |
| US-12350352-B2 | Composition for surface modification | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2025-07-08 | — | — | US | claimed |
| EP-4100001-B1 | CONTROLLED RELEASE SYSTEM OF PHYTOCANNABINOIDS FORMULATIONS SOLUBLE IN AQUEOUS MEDIA, METHODS AND USES THEREOF | I MED S COOP (ES) | 2025-06-25 | — | — | EP | claimed |
| EP-3342395-B1 | COMPOSITION FOR HAIR SURFACE MODIFICATION | LG HOUSEHOLD & HEALTH CARE LTD (KR) | 2024-08-07 | — | — | EP | claimed |
| EP-4406617-A2 | COMPOSITION FOR SURFACE MODIFICATION | LG Household & Health Care Ltd. (KR) | 2024-07-31 | — | — | EP | claimed |
| US-11612552-B2 | Composition for surface modification | LG HOUSEHOLD & HEALTH CARE LTD. | 2023-03-28 | — | — | US | claimed |
| US-20230088314-A1 | Composition For Surface Modification | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2023-03-23 | — | — | US | claimed |
| US-10660972-B2 | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases | AMICUS THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | claimed |
| US-20170319710-A1 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | AMICUS THERAPEUTICS, INC. (US) | 2017-11-09 | — | — | US | claimed |
| EP-2717919-B1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES CO (US) | 2016-08-03 | — | — | EP | claimed |
| US-9011970-B2 | Process for preparing articles having anti-fog layer by layer coating and coated articles having enhanced anti-fog and durability properties | ESSILOR INTERNATIONAL (FR) | 2015-04-21 | — | — | US | claimed |
| US-20140302001-A1 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | CALLIDUS BIOPHARMA, INC. (US) | 2014-10-09 | — | — | US | claimed |
| EP-2598585-B1 | PROCESS FOR PREPARING ARTICLES HAVING ANTI-FOG LAYER BY LAYER COATING AND COATED ARTICLES HAVING ENHANCED ANTI-FOG AND DURABILITY PROPERTIES | ESSILOR INT (FR) | 2014-07-02 | — | — | EP | claimed |
| EP-2598585-A1 | PROCESS FOR PREPARING ARTICLES HAVING ANTI-FOG LAYER BY LAYER COATING AND COATED ARTICLES HAVING ENHANCED ANTI-FOG AND DURABILITY PROPERTIES | Essilor International (Compagnie Générale D'Optique) (FR) | 2013-06-05 | — | — | EP | claimed |
| WO-2012013739-A1 | PROCESS FOR PREPARING ARTICLES HAVING ANTI-FOG LAYER BY LAYER COATING AND COATED ARTICLES HAVING ENHANCED ANTI-FOG AND DURABILITY PROPERTIES | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2012-02-02 | — | — | WO | claimed |
| US-20120027933-A1 | Process for Preparing Articles Having Anti-Fog Layer by Layer Coating and Coated Articles Having Enhanced Anti-Fog and Durability Properties | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2012-02-02 | — | — | US | claimed |
| US-20070248567-A1 | Protein crosslinkers, crosslinking methods and applications thereof | AUGMENIX, INC. | 2007-10-25 | — | — | US | claimed |
| EP-3711743-B1 | CATIONIC CELLULOSE AND COMPOSITION FOR TREATING HAIR, SKIN, OR FIBER INCLUDING SAME | LG HOUSEHOLD & HEALTH CARE LTD (KR) | 2025-07-23 | — | — | EP | disclosed |
| US-5366591-A | Cyclic N-sulfatoimide | WEYERHAEUSER | 1994-11-22 | — | — | US | disclosed |
| WO-1993014261-A1 | METHOD FOR CROSSLINKING INDIVIDUALIZED CELLULOSE FIBRES | WEYERHAEUSER COMPANY (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350352-B2 | Composition for surface modification | CUTA, PTMS, DNMT1 | MAP3K14 3032/4885CRBN 568/4885DDB1 1081/4885 |
| US-20230088314-A1 | Composition For Surface Modification | CUTA, PTMS, DNMT1 | MAP3K14 3032/4885CRBN 568/4885DDB1 1081/4885 |
| US-11612552-B2 | Composition for surface modification | CUTA, PTMS, DNMT1 | MAP3K14 3032/4885CRBN 568/4885DDB1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.